A novel therapeutic approach to treat pandemic obesity and its comorbidities
Obesity is a major burden for the billions of affected individuals since existing anti-obesity medical therapy is unsatisfactory both in terms of efficacy and safety. Josua Jordi and his team identified a set of small molecules with remarkable in vivo potency and selectivity in two vertebrate models. Within the Fellowship project, the team were able to solidify the promising candidate compounds using e.g. proof-of-concept studies in rats. In 2018 Josua Jordi and his co-founder Simon Breitler founded the UZH spinoff EraCal Therapeutics.
UZH Host Professor: Prof. Thomas Lutz
Start date: 09/2018